Introduction: Immunotherapy is emerging as a new modality of treatment for cutaneous warts by enhancing cell mediated immunity. Immunotherapy is replacing destructive modalities such as electrocautery and cryotherapy due to its advantages over former, such as affordability, easy availability and minimal downtime. The most common immunotherapeutic agents for warts include intralesional vitamin D3, Measles Mumps Rubella (MMR), Bacille calmette-Guerin (BCG) and Purified protein derivative (PPD). Aim: This study aims to evaluate the safety and efficacy of intralesional vitamin D3 for the treatment of cutaneous warts.